Answers are grounded in this paper and cite their sources.
These NCCN Guidelines Insights highlight the important updates specific to the management of HER2-positive metastatic breast cancer in the 2013 version of the NCCN Clinical Practice Guidelines in Oncology for Breast Cancer. These include new first-line and subsequent therapy options for patients with HER2-positive metastatic breast cancer.
No takes yet. Share an insight, caveat, or question.
Theriault et al. (2013) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: